tbuckley/cabot-search huggingface dataset:
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies
Authors: Ibiayi Dagogo-Jack, Antonello Abbattista, John F. Murphy, Stan Krulewicz, Andrew Do, Jennifer Peterson, Jessica J. Lin, Justin F. Gainor, Rossella Messina, Elizabeth A. Krueger, Holger Thurm, Beow Y. Yeap
Journal: Journal of Thoracic Oncology (2022)

The safety profile of lorlatinib includes neurocognitive adverse events (NAEs). Baseline factors associated with developing NAEs remain poorly characterized.Records from patients who received lorlatinib through prospective studies at Massachusetts General Hospital (MGH, n = 124) or the phase 1/2 B7461001 (NCT01970865; n = 248) study were reviewed to identify potential associations between comorbidities, baseline medications, and NAEs.Most patients experienced a NAE (MGH: 60%, B7461001: 49%). Cognitive effects occurred in 40% and 29% of patients in the MGH and B7461001 cohorts, respectively. Brain metastases (p = 0.008), brain radiation (p = 0.033), psychiatric illness (p = 0.008), psychiatric medications (p < 0.001), antiepileptics (p < 0.001), and stimulants (p = 0.026) were associated with developing cognitive effects in B7461001. Mood effects occurred in 36% and 23% of patients in the MGH and B7461001 cohorts, respectively. In the MGH cohort, psychiatric illness (p = 0.02) and stimulants (p = 0.01) were associated with developing mood effects whereas brain surgery (p = 0.020), psychiatric medications (p < 0.001), benzodiazepines (p = 0.002), and sedatives (p = 0.034) were associated with developing mood effects in B7461001. Psychotic effects were infrequent (MGH: 3%, B7461001: 9%) and were associated with brain surgery in the MGH cohort (p = 0.001) and age in B7461001 (p = 0.014). Speech effects were observed in 23% and 11% of patients in the MGH and B7461001 cohorts, respectively. Brain radiation (p = 0.012) and antiepileptics (p < 0.001) were associated with speech effects in B7461001. Dose reductions were implemented for 52% and 18% of patients with NAEs in MGH and B7461001 cohorts, respectively, with mitigating effect.Neurocognitive effects from lorlatinib are common. Lorlatinib-related NAEs may be influenced by multiple factors, including brain metastases, brain radiation, psychiatric illness, and use of neurotropic medications.
Chest Pain Evaluation Units
Authors: James W. Hoekstra
Journal: JAMA (1997)

In this issue ofThe Journal, Roberts et al<sup>1</sup>present the results of a randomized controlled clinical trial comparing the cost for evaluation of patients with chest pain in an emergency department—based accelerated diagnostic protocol (ADP) vs traditional hospitalization. This article, despite its limitations, addresses some of the controversies in the expanding literature support for emergency department—based ADPs and chest pain evaluation units (CPEUs) as feasible, safe, and effective alternatives to hospital admission for patients with chest pain. Approximately 15% of emergency departments in the United States have established CPEUs. This percentage has been increasing as managed care programs and diminishing resources dictate the need for cost-effective approaches to the care of patients with chest pain. The development of CPEUs for the evaluation of patients with chest pain makes intuitive sense. Patients with possible acute coronary syndrome (ACS) remain a significant challenge for emergency physicians. The inadvertent release of 2%
Awards, Appointments, Announcements
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Awards, Appointments, Announcements Get access JNCI: Journal of the National Cancer Institute, Volume 87, Issue 17, 6 September 1995, Pages 1287–1288, https://doi.org/10.1093/jnci/87.17.1287 Published: 06 September 1995
Fellowships, Grants, Awards
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Fellowships, Grants, Awards Get access JNCI: Journal of the National Cancer Institute, Volume 84, Issue 11, 3 June 1992, Pages 906–908, https://doi.org/10.1093/jnci/84.11.906 Published: 03 June 1992
Assaults in South East London
Authors: M A Hocking
Journal: Journal of the Royal Society of Medicine (1989)

A survey was performed of 425 consecutive patients attending Lewisham Hospital as a result of deliberate physical violence. Eighty-two per cent attended 'out of hours', and in at least 50% alcohol was a contributing factor. Less than half the incidents were reported to the police. Fifteen per cent of the attacks were due to knives and accounted for 47% of the admissions and 90% of the serious injuries. The results support the view that it is becoming common for youths to be armed. Assault victims, particularly those with knife wounds place a considerable burden on hospital resources. Accident and Emergency departments are ideal places to monitor the epidemiology of assaults.
Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney
Authors: Qiaohui Chen, Yayun Nan, Yuqi Yang, Zuoxiu Xiao, Min Liu, Jia Huang, Yuting Xiang, Xingyu Long, Tianjiao Zhao, Xiaoyuan Wang, Qiong Huang, Kelong Ai
Journal: Bioactive Materials (2022)

Currently, there are no clinical drugs available to treat acute kidney injury (AKI). Given the high prevalence and high mortality rate of AKI, the development of drugs to effectively treat AKI is a huge unmet medical need and a research hotspot. Although existing evidence fully demonstrates that reactive oxygen and nitrogen species (RONS) burst at the AKI site is a major contributor to AKI progression, the heterogeneity, complexity, and unique physiological structure of the kidney make most antioxidant and anti-inflammatory small molecule drugs ineffective because of the lack of kidney targeting and side effects. Recently, nanodrugs with intrinsic kidney targeting through the control of size, shape, and surface properties have opened exciting prospects for the treatment of AKI. Many antioxidant nanodrugs have emerged to address the limitations of current AKI treatments. In this review, we systematically summarized for the first time about the emerging nanodrugs that exploit the pathological and physiological features of the kidney to overcome the limitations of traditional small-molecule drugs to achieve high AKI efficacy. First, we analyzed the pathological structural characteristics of AKI and the main pathological mechanism of AKI: hypoxia, harmful substance accumulation-induced RONS burst at the renal site despite the multifactorial initiation and heterogeneity of AKI. Subsequently, we introduced the strategies used to improve renal targeting and reviewed advances of nanodrugs for AKI: nano-RONS-sacrificial agents, antioxidant nanozymes, and nanocarriers for antioxidants and anti-inflammatory drugs. These nanodrugs have demonstrated excellent therapeutic effects, such as greatly reducing oxidative stress damage, restoring renal function, and low side effects. Finally, we discussed the challenges and future directions for translating nanodrugs into clinical AKI treatment.
The Acquired Immune Deficiency Syndrome: The Ever-Broadening Clinical Spectrum
Authors: Anthony S. Fauci
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Psychiatry in Medical Education
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: A systemic, splanchnic and renal hemodynamic study
Authors: Antoine Hadengue, Richard Moreau, Yannick Bacq, Christophe Gaudin, Alain Braillon, Didier Lebrec
Journal: Hepatology (1991)

We studied the effects of fenoldopam, a selective dopamine DA 1 agonist on systemic and splanchnic hemodynamics, renal blood flow and sodium excretion in 12 patients with alcoholic cirrhosis and ascites. Hepatic, azygos and renal veins were catheterized before and after intravenous administration of fenoldopam, 0.05 μg/kg/min for 1 hr and increased to 0.1 μg/kg/min for another hour. Mean arterial pressure progressively decreased (from 83 ± 7 to a minimum of 77 ± 8 mm Hg 100 min after starting the infusion) but returned to baseline level at 120 min. Plasma norepinephrine and renin activity increased (respectively from 567 ± 297 to 919 ± 375 pg/ml, p &lt; 0.05, and from 17 ± 14 to 23 ± 15 ng/ml/hr, p &lt; 0.05). Renal blood flow, urine output or sodium excretion did not change. Sodium output decreased at 1 hr from 6.9 μmol/min to 4.0 μmol/min, p &lt; 0.05. Both hepatic venous pressure gradient and azygos blood flow significantly increased by 21%. We conclude that the acute administration of fenoldopam did not improve renal hemodynamics or function in patients with cirrhosis and ascites. In addition, dopamine DA 1 agonism caused further increases in norepinephrine concentration and plasma renin activity. Portal pressure also increased, probably because of an increase in mesenteric blood flow. These results question the renal benefit and raise concern about the use of dopamine agonists in patients with cirrhosis and ascites. (Hepatology 1991;13:111-116).
Immune Response to Inactivated Syngeneic Mammary Adenocarcinoma Cells. I. Role and Regulation of Antibody Synthesis in DBA/2 Mice&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1980)

The Immunogenicities of irradiated T1699 murine mammary adenocarcinoma cells (XR-T1699) and mitomycin C-treated T1699 cells (T1699m) were compared with respect to eliciting humoral immunity, cell-mediated immunity, and protection against subsequent sc challenge with untreated T1699 tumor cells (T1699u) in the syngeneic host (DBA/2 mice). Treatment with 103–107 T1699m failed to Induce any immunity against subsequent challenge with viable T1699u, whereas 106-107 XR-T1699 sensitized the host to later challenge with T1699u. Although both T1699m- and XR-T1699-sensitized mice displayed a delayed hypersensitivity response to soluble T1699 antigen as determined by footpad swelling, only XR-T1699-immunized mice developed detectable levels of anti-T1699 antibody, as measured by indirect immunofluorescence. The antibody-dependent cellular cytotoxicity (ADCC) titer of sera from XR-T1699-immunized mice peaked at day 11 and declined by day 20, whereas sera from T1699m-sensitized mice showed no detectable ADCC activity. Sera from mice with progressing T1699u tumors showed high levels of ADCC activity at all times tested. The immunity induced by XR-T1699 injection was shown to be specific for T1699 tumor cells and not limited to the anatomic area of immunization. The results are discussed In terms of the role of antibody as the primary protective mechanism in sensitization in the T1699 tumor model.
Is There a Need for `Catch-Up' Polio Vaccination in Preadolescence?
Authors: Steven G. Fite Wassilak
Journal: JAMA (1981)

The introduction and widespread use of the inactivated and live poliovirus vaccines in the United States have brought about a dramatic reduction in the incidence of poliomyelitis: More than 20,000 paralytic cases were reported in 1952, whereas the current annual average is less than 20.<sup>1,2</sup>As a consequence of this extraordinary degree of control, there is virtually no wild poliovirus circulation in the United States; individual protection from wild virus introduction depends on successful vaccination. Data available in 1976 and 1977 indicated that a substantial proportion (perhaps one third) of American children younger than 5 years had not received a full course of trivalent oral polio vaccine (TOPV).<sup>3,4</sup>These and other findings led a study group convened by the Institute of Medicine, National Academy of Sciences, to recommend routine administration of an additional dose of TOPV at age 11 to 12 years.<sup>5</sup>This dose was proposed not
Risk Factors for HIV-1 Seroconversion Among Young Men in Northern Thailand
Authors: David D. Celentano
Journal: JAMA (1996)

<h3>Objective.</h3> —To identify behavioral and sociodemographic risk factors for incident human immunodeficiency virus—1 (HIV-1) infection among healthy young men in northern Thailand. <h3>Design.</h3> —Men inducted into military service in northern Thailand in May and November 1991 were followed at 6-month intervals until discharge 2 years later. Trained nonmilitary interviewers identified risk factors for HIV-1 infection through interviews with the men. <h3>Setting.</h3> —Thirteen military bases in northern Thailand. <h3>Participants.</h3> —A total of 1932 seronegative men, aged 19 to 23 years (average age, 21 years) at enrollment, conscripted into the Royal Thai Army and Air Force from six upper-northern Thai provinces. <h3>Main Outcome Measures.</h3> —Human immunodeficiency virus—1 seroincidence as determined through enzyme-linked immunosorbent assay and verified by Western blot, and univariate and multivariate analyses of risk factors related to HIV-1 incidence. <h3>Results.</h3> —A total of 85 men seroconverted to HIV-1 over the period of observation, giving an incidence rate of 2.43 per 100 person-years. Factors strongly associated with HIV-1 seroconversion were frequency of visits to female commercial sex workers (CSWs), sex with men, and incident sexually transmitted diseases (STDs). High frequency of condom use showed a significant (<i>P</i>&lt;.001) protective effect for HIV-1 incidence among men with a history of recent sex with female CSWs in univariate analysis, but a multivariate model demonstrated no difference in HIV-1 seroconversion rates by consistency of condom use. Multivariate analysis incorporating condom use showed that having sex with men (adjusted relative risk [RR], 2.59; 95% confidence interval [CI], 1.08 to 6.25), having sex with CSWs (adjusted RR ranged from 2.54 [95% CI, 1.81 to 3.58] to 2.74 [95% CI, 1.56 to 4.81]), and incident STDs (adjusted RR, 2.38 [95% CI, 1.31 to 4.32]) to be predictors of incident HIV-1 infection. Substance use was not associated with HIV-1 seroconversion rates in multivariate analysis. <h3>Conclusion.</h3> —The HIV-1 incidence in this cohort of young men appears to be primarily attributable to having sex with female CSWs. Condom use provided some protection, although not in multivariate analysis; however, condom use has previously been shown likely to be useful in preventing HIV-1 transmission. Thus, programs to increase effective condom use in brothels are essential. Efforts to extend condom use to non-CSW partners are especially needed. More effective prevention and treatment of STDs may also be necessary to decrease HIV-1 infection in this population. (<i>JAMA</i>. 1996;275:122-127)
A Treatise on Diagnostic Methods of Examination.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bacteriological Technique: A Laboratory Guide for Medical, Dental, and Technical Students.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Problems of Old Age
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Report: Health Care Reform Must Affirm 'Right'
Authors: Charles Marwick
Journal: JAMA (1993)

DISCUSSIONS about health care reform in the United States have, so far, been based mainly on economics and technical considerations of organization and control. How much will it cost? What should be covered? How will it be administered? And, above all, what are acceptable measures to contain costs? This is much too narrow a view of the vital issue, holds a newly released report from the American Association for the Advancement of Science (AAAS), the Washington, DC—based group that is the world's largest federation of scientific and engineering societies. One of the stated goals of the AAAS is "to improve the effectiveness of science in the promotion of human welfare." Its new report from the "Right to Health Care" project maintains that "there is a right to a basic and adequate standard of health care consistent with society's level of resources." If this right is to be meaningful, the report
New and Nonofficial Remedies, 1935
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Two doses of paclitaxel and statistical analysis: try, try, try again.
Authors: W Akerley
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.1.408 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8996170 Two doses of paclitaxel and statistical analysis: try, try, try again. W AkerleyxW AkerleySearch for articles by this author https://doi.org/10.1200/JCO.1997.15.1.408 PDF "Two doses of paclitaxel and statistical analysis: try, try, try again.." Journal of Clinical Oncology, 15(1), pp. 408–409© 1997 by American Society of Clinical Oncology